SLAMF9

Across TCGA pan-cancer cohorts, SLAMF9 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated SLAMF9 data layer compared with 3 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SLAMF9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SLAMF9 expression acts as an unfavorable survival marker, although some lineages such as DLBC and ESCA show a favorable association.

ACC, LUAD, and UCS are the cancer types where SLAMF9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Tertile	All	0.378	0.739	<.001	103	view →
LUAD	OS	Tertile	III,IV	0.531	0.778	.002	75	view →
UCS	OS	Tertile	III,IV	0.249	0.709	.003	60	view →
KIRC	OS	Tertile	All	0.807	0.924	<.001	53	view →
DLBC	DFS	Tertile	III,IV	1.000	0.074	.001	52	view →
ESCA	DFS	Median	IV	0.634	0.205	.006	46	view →
KICH	DFS	Quartile	II,III,IV	0.188	0.928	<.001	45	view →
LGG	DFS	Tertile	All	0.642	0.792	<.001	29	view →
PAAD	OS	Median	All	0.280	0.522	.001	29	view →
MESO	OS	Median	IV	0.247	0.585	.012	26	view →
SKCM	OS	Median	All	0.740	0.825	.001	25	view →
THCA	DFS	Median	All	0.784	0.899	.005	24	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

SLAMF9–ACC (OS)

Open the ACC breakdown →